Datavault AI Expands Data-Driven Outcome Healthcare-focused Blockchain and Data Monetization License With DataMeds AI

Datavault AI Inc., a provider of data monetization, credentialing, digital engagement, and real-world asset tokenization technologies, announced that it has amended its definitive agreement with DataMeds AI, Inc. to increase its PharmacyChain blockchain-related technology licensing relationship beyond pharmaceutical delivery to include entirely unencumbered commercial medical care, healthspan and wellness applications of Datavault AI’s intellectual property.

The behavioral healthcare patent portfolio being acquired was developed at La Frontera, Arizona, by the late Senator David T. Bradley and Dr. Dan Ranieri, and covers healthcare and pharmaceutical logistics, IoT population health, and in-home patient monitoring with AI-driven behavioral health intuitions and interventions. DataMeds is acquiring the portfolio in concurrent transactions with EOS Technology Holdings and Scilex.

“Our business model depends on extracting greater value from the information we generate every day. Datavault AI’s platform gives us confidence that we can transform data into a strategic asset for our future customers, not just for operational insights, but as a foundation for future commercial opportunities and customer acquisition strategies. We see this as the key step in modernizing how organizations think about data ownership and monetization in healthcare,” said Gerald Commissiong, Interim Co-CEO of DataMEDS.

Nathaniel T. Bradley, CEO of Datavault AI, said, “Extending our data monetization and tokenization platform into commercial healthcare, healthspan and wellness is a natural next step for patient-controlled data. DataMEDS gives us a focused path to put that technology to work so individuals have a say over how their own medical information is transacted.”

In the condition of the amended definitive agreement, Datavault AI receives common shares representing approximately 19.9% of DataMEDS common stock upon completion of the previously disclosed associated transactions with Scilex Holding Company, EOS Technology Holdings, Inc. and HealthBridge Advisors, LLC, instead of preferred shares. The alteration was made to change common shares in place of preferred shares to optimize the transaction for tax purposes. The share issuance remains subject to satisfaction of the closing conditions, involving the acquisition of two QOLPOM intellectual property portfolios from EOS Technology Holdings and the acquisition of a controlling interest in Tollo Health LLC from HealthBridge Advisors. The value of the share issuance to Datavault AI is expected to be considered as revenue upon the common share issuance.

DataMEDS, formerly Wellgistics Health, Inc., announced that it had finished its corporate name change, and stated that trading on the Nasdaq Capital Market under the symbol ‘MEDS’ began in July 2026. DataMEDS is issuing a dividend of 50 Dream Bowl Meme Coin tokens for each share of DataMEDS common stock owned as of the August 7, 2026 record date, which is subject to change at DataMEDS’ sole discretion.

The increasing collaboration is designed to extend Datavault AI’s data monetization and real-world asset tokenization skills into the DataMEDS medical care data environment, helping patient-driven medical care information access and data-transaction models in the pharmacy, healthcare, laboratory, and wearables settings. This comes as healthcare data already represents approximately 30% of the world’s data volume and is growing at an estimated 36% yearly, making substantial opportunities for patient-controlled monetization and real-world asset tokenization within a global health and wellness market exceeding $7 trillion. The organization executed the amended agreement ahead of completing the remaining closing conditions in order to accelerate operational execution, including access to Datavault AI’s technology associations.

According to Towards Healthcare, the healthcare data monetization market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 633.34 million in 2026 to approximately USD 2203.71 million by 2035. Estimated to grow at a CAGR of 14.86% starting from 2026 to 2035. Data monetization transforms medical care data into value, driving advancement in patient care, operational effectiveness, and novel revenue opportunities. This approach can enable drug discovery, targeted medicine, population health, and operational effectiveness. Lessen expenses through risk mitigation. Improved understanding of consumer preferences. Raise growth via personalized product providing. Data monetization a significant tool for data custodians to achieve their economic goals while fostering innovation and particular progress.

About DataMeds AI, Inc.

DataMeds AI, Inc. is a leading Health IT organization that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an advanced healthcare experience for customers. Headquartered in Tampa, Fla., DataMeds AI integrates the artificial intelligence platform EinsteinRx and blockchain-enabled smart contracts platform PharmacyChain into the Health Lives Here Mobile application and Tollo Health.

About Datavault AI

Datavault AI leads AI-driven data experiences, valuation, and monetization in the Web 3.0 environment. The Company’s cloud-driven platform delivers comprehensive services through its collaborative Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division involves WiSA, ADIO, and Sumerian patented technologies for spatial and multichannel wireless HD sound. The Data Science Division harnesses Web 3.0 and high-performance calculation for experiential data insight, valuation, and secure monetization in industries involving sports and entertainment, biotech, education, fintech, real estate, energy, and healthcare. The Information Data Exchange (IDE) allows Digital Twins and secure NIL licensing, fostering responsible AI with integrity. Datavault AI’s customizable technology suite provides AI/ML automation, third-party integration, analytics, marketing automation, and publicity monitoring.

A recent report by Towards Healthcare highlights that the healthcare data monetization market is growing, as it enables consumers to control their medical care data and to sell their data to biopharmaceutical companies, investigators, or healthcare providers. Healthcare organizations monetize their data by sharing access to their clinical data with biopharmaceutical organizations, research organizations, and other interested parties in compliance with relevant government standards. Researchers apply this leverage to detect novel management, drugs, and therapies. Data monetization by offering access to different data analytics tools, helping organizations derive insights from their information.